The late complications of totally implantable central venous access ports: The results from an Italian multicenter prospective observation study

Molin, Alberto Dal; Rasero, Laura; Guerretta, Linda; Perfetti, Elisa; Clerico, Mario

doi:10.1016/j.ejon.2010.11.007

Cited by 44 publications

(51 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This conclusion is also in accordance with other previous studies (1,15,16). In our case series, the overall complication rate was 6.86% (205/1,996) over the entire device duration.…”

Section: Discussionsupporting

confidence: 81%

Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients

Liu

Wang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Totally implantable venous access port systems (TIVAPS) are widely used in breast cancer patients. However, complications are frequent and may necessitate device replacement or removal, resulting in additional patient stress and treatment delays. The aim of the present study was to investigate possible risk factors for complications. A total of 2,996 consecutive female breast cancer patients, with a median age of 50.2 years (range, 21.2-85.5 years) were enrolled in this observational, single-centre study between December, 2008 and April, 2014. TIVAPS implantation was principally performed using local anaesthesia and the blind puncture or Seldinger technique through internal jugular or subclavian vein access. A retrospective chart review was conducted to obtain information associated with TIVAPS and patient data. Insertion performed by blind puncture and Seldinger technique had a success ratio of 96.34 and 99.80%, respectively (χ 2 =29.905, P<0.001). However, the success ratio of the puncture technique group was 99.76% when the TIVAPS was implanted in the right internal jugular vein. The most common complications were late complications, with an overall incidence rate of 5.41% (162/2,996) during the entire device duration. The most common late complications included fibrin formation (1.84%, 55/2,996), port-related bacteraemia (1.44%, 43/2,996) and deep vein thrombosis (0.63%, 19/2,996). No patient died during the study. Our results demonstrated that insertion of TIVAPS by blind puncture or the Seldinger technique through internal jugular or subclavian vein access is convenient, and insertion by the Seldinger technique through the right internal jugular vein is the preferred method. Therefore, TIVAPS is safe for continuous infusional chemotherapy regimens for breast cancer patients.

show abstract

“…This conclusion is also in accordance with other previous studies (1,15,16). In our case series, the overall complication rate was 6.86% (205/1,996) over the entire device duration.…”

Section: Discussionsupporting

confidence: 81%

Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients

Liu

Wang

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, regarding CVAD, cancer patients feel very cautious and insecure [24]. Maybe, they recognize that CVADs like TIAP require utmost care to minimize not only infection risk [25] but also other complications like catheter malfunction or catheter-related thromboembolism [26][27][28]. Patients could also be worried for complications occurring during the implant procedure [29].…”

Section: Introductionmentioning

confidence: 97%

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

Piredda

Biagioli

Giannarelli³

et al. 2015

Support Care Cancer

View full text Add to dashboard Cite

The interventions provided resulted effective in decreasing patients' physiological indicators of anxiety immediately after TIAP implantation and improving patients' knowledge about TIAP immediately and at 3 months. Adding answers to clarification questions to the booklet was not more effective than the booklet alone. A well-designed booklet with attention both to scientific content and to communication techniques is useful in improving patients' knowledge about TIAP and reducing anxiety.

show abstract

“…Chemotherapy was started on the first day of “PORT” catheter in 74% of patients in the “PORT” study group. The various complications in our study as compared with other studies 31 in the “PORT” study group in descending order are as follows: 4 patients (4%) developed early infection, 4 (4%) developed late infection, 22,23,26,30 4 (4%) developed BSI, 2 (2%) developed local skin infection at the “PORT” insertion site, 2 (2%) developed dislodgment of the “PORT” catheter, 2 (2%) developed fracture of the “PORT” catheter, 1 (1%) developed thrombosis, 24 and 1 developed recurrent pleural effusion. 29 …”

Section: Discussionmentioning

confidence: 55%

A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience

Madabhavi

Patel

Sarkar

et al. 2017

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background:Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology.Materials and methods:This is a prospective observational study, which collected data of patients who require “PORT” catheter insertion for any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period.Aims and objectives:The main objective of this study was to study the various complications and outcomes related to “PORT” catheters.Results:“PORT” catheter was inserted in 100 patients and was most commonly used in solid malignancies (n = 86, 86%), followed by hematologic malignancies (n = 14, 14%). Among the solid malignancies, breast cancer (38, 38%) was the most common underlying disease, whereas among the hematologic malignancies, acute lymphoblastic leukemia (6, 6%) was the most common underlying disease for “PORT” catheter insertion. Chemotherapy was started on the first day of “PORT” catheter in 74% of patients in the “PORT” study group. The various complications developed in the “PORT” study group in the descending order are as follows: 4 patients (4%) developed early infection (⩽30 days after “PORT” placement), 4 (4%) late infection (⩾30 days after “PORT” placement), 4 (4%) bloodstream infection, 2 (2%) local skin infection at the “PORT” insertion site, 2 (2%) dislodgment of the “PORT” catheter, 2 (2%) fracture of the “PORT” catheter, and 1 recurrent pleural effusion. One patient (1%) developed thrombosis as the complication of “PORT” catheter insertion.Conclusions:The most disturbing aspect of treatment for a patient with cancer is multiple painful venipunctures made for administration of cytotoxic agents, antibiotics, blood products, and nutritional supplements. The focus of this prospective observational research is to study the various underlying diseases for which “PORT” catheter is needed in different solid and hematologic malignancies and the various complications and outcomes in pediatric and adult patients with cancer.

show abstract

The late complications of totally implantable central venous access ports: The results from an Italian multicenter prospective observation study

Cited by 44 publications

References 16 publications

Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients

Totally implantable venous access port systems and associated complications: A single-institution retrospective analysis of 2,996 breast cancer patients

Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial

A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience

Contact Info

Product

Resources

About